[Experience in long-term use of berodual in the treatment of patients with chronic obstructive bronchitis].
OBJECTIVE
To study clinical efficiency of 12-month administration of berodual in chronic obstructive bronchitis (COB).


METHODS
The trial entered 33 patients with at least 2-year history of COB and forced expiratory volume per 1 sec (FEV1) not less than 45% of normal value.


RESULTS
The best response of clinical parameters and external respiration was observed throughout 3 weeks of berodual inhalations. Dyspnea and cough were cured by the end of the treatment in 40 and 26% of the patients, respectively. Exercise tolerance has improved, FEV1 has increased for the year from 71.9 to 79.1%.


CONCLUSIONS
Long-term berodual monotherapy is able to inhibit progression of bronchial obstruction and symptoms of COB.
Shmelev
E I
EI
Khmel'kova
N G
NG
Nonikov
D V
DV
Melent'eva
E M
EM
Abubikirov
A F
AF
Makarova
V L
VL
Mazaeva
L A
LA
Ushakova
T I
TI
D000328:Adult; D000368:Aged; D001991:Bronchitis / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D004338:Drug Combinations; D005260:Female; D005280:Fenoterol / Q000008:administration & dosage*; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D012129:Respiratory Function Tests; D013997:Time Factors
D001993:Bronchodilator Agents; D004338:Drug Combinations; C030809:fenoterol, ipratropium drug combination; D005280:Fenoterol; D009241:Ipratropium